Methods for treating Filoviridae virus infections

Patent metadata

Field	Value
Publication number	US-9724360-B2
Application number	US-201514926062-A
Country	US
Kind code	B2
Filing date	Oct 29, 2015
Priority date	Oct 29, 2014
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV:

The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

First claim

What is claimed is:

1. A compound:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers and optionally other therapeutic agents.

4. The pharmaceutical composition according to claim 3 wherein the other therapeutic agents is selected from the group consisting of ribavirin, palivizumab, motavizumab, RSV-IGIV (RespiGam®), MEDI-557, A-60444, MDT-637, BMS-433771, amiodarone, dronedarone, verapamil, Ebola Convalescent Plasma (ECP), TKM-100201, BCX4430 ((2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol), favipiravir (also known as T-705 or Avigan), T-705 monophosphate, T-705 diphosphate, T-705 triphosphate, FGI-106 (1-N,7-N-bis[3-(dimethylamino)propyl]-3,9-dimethylquinolino[8,7-h]quinolone-1,7-diamine), JK-05, TKM-Ebola, ZMapp, rNAPc2, VRC-EBOADC076-00-VP, OS-2966, MVA-BN filo, brincidofovir, Vaxart adenovirus vector 5-based ebola vaccine, Ad26-ZEBOV, FiloVax vaccine, GOVX-E301, GOVX-E302, ebola virus entry inhibitors (NPC1 inhibitors), rVSV-EBOV, and mixtures thereof.

5. The pharmaceutical composition according to claim 4 wherein the other therapeutic agents is ZMapp.

6. A method of treating a Filoviridae infection in a human in need thereof comprising administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof of claim 1 or a pharmaceutical composition of any one of claims 3 to 5 .

7. The method of claim 6 wherein the Filoviridae infection is an ebolavirus infection.

8. The method of claim 6 wherein the Filoviridae infection is a Marburg virus infection.

Assignees

• Gilead Sciences Inc

Inventors

• Chun Byoung Kwon
• Clarke Michael O' Neil Hanrahan
• Doerffler Edward
• Hui Hon Chung
• Jordan Robert
• Mackman Richard L
• Parrish Jay P
• Ray Adrian S
• Siegel Dustin

Classifications

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title